This week my Safari portfolio is looking to add a company from the Healthcare sector.
The Healthcare sector includes ten industries all related to testing, diagnosing and treating what ails us. The healthcare industries are: biotechnology; diagnostics & research; drug manufacturers (major and specialty & generic); healthcare plans; long-term care facilities; medical care; medical devices, medical distribution; medical supplies.
Today I’m reviewing a Japanese drug manufacturer – specialty & generic. It’s a large-cap stock, Mitsubishi Tanabe Pharma Corporation. Its trading ticker symbol is MTZXF (ADR, which is more actively traded, is MTZPY).
Mitsubishi Tanabe Pharma researches and develops, manufactures, procures, and sells pharmaceuticals in Japan, Europe, North America, other Asian countries, and internationally. The company offers drugs and vaccines for autoimmune, diabetes, kidney, central nervous system, and other disease treatment, as well as sells generic drugs and over-the-counter (OTC) products.
The company was founded in 1678 and is headquartered in Osaka, Japan. Mitsubishi Tanabe Pharma Corporation is a subsidiary of Mitsubishi Chemical Holdings Corporation.
Three key data points measure dividend equities like Mitsubishi Tanabe Pharma:
(1) Price
(2) Dividends
(3) Returns
After those three, four more keys will unlock an equity or fund in which to invest. Those first three primary keys, however, best tell whether a company has made, is making, and will make money.
MTZXF Price
Mitsubishi Tanabe’s price at yesterday’s market close was $20.45 per share. A year ago its price was $20.15. That is a gain of $0.30 per share in the past year. Assuming Mitsubishi Tanabe’s price gains at the same pace this year, its price would grow from $20.45 to $20.75 by March 2019.
MTZXF Dividends
Mitsubishi Tanabe’s most recent annual dividend was $0.25 declared in November, and paid in June, 2017. The Mitsubishi Tanabe estimated annual dividend for 2018 is estimated at $0.25 to be paid in June.
